Related Experiment Video
Updated: Aug 14, 2026
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Effect of erythropoietin on cardiovascular diseases
1Department of Medicine, Division of Nephrology and Dialysis, University of Vienna, Vienna, Austria. Gere.Sunder-Plassmann@akh-wien.ac.at
Insights
Renal anemia significantly impacts cardiac health in dialysis patients, contributing to heart dysfunction and death. While treating anemia improves symptoms, preventing it may be more effective for long-term outcomes.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiac diseases are a leading cause of death in long-term dialysis patients, with left ventricular dysfunction present in 80%.
- Renal anemia is a significant risk factor for cardiac complications, worsening with declining renal function and dialysis.
- Cardiovascular consequences of anemia manifest early in renal failure and progress during dialysis therapy.
Purpose of the Study:
- To evaluate the impact of anemia correction on cardiac function and mortality in chronic renal failure patients undergoing dialysis.
- To assess the effects of hemoglobin normalization on left ventricular structure and cardiovascular outcomes.
- To explore the relationship between recombinant human erythropoietin (rHuEPO) therapy, hypertension, and overall patient survival.
Main Methods:
- Observational study analyzing data from chronic renal failure patients with severe anemia (hemoglobin <10 g/dL).
- Assessment of cardiac parameters including cardiac output, left ventricular mass, and diameters before and after anemia correction (hemoglobin >11 g/dL).
- Review of existing literature and clinical guidelines (European Best Practice Guidelines) regarding anemia management and cardiovascular outcomes.
Main Results:
- Partial correction of anemia improved cardiac output, left ventricular mass, diameters, and symptoms in patients with severe anemia.
- Normalization of hemoglobin levels showed minimal effect on regression of left ventricular hypertrophy and dilation.
- Hemoglobin normalization did not demonstrate benefits in all-cause mortality or survival for end-stage renal disease patients with heart failure or ischemic heart disease.
- Recombinant human erythropoietin (rHuEPO) therapy is associated with hypertension, which is generally manageable.
Conclusions:
- Partial anemia correction benefits cardiac function and symptoms in dialysis patients, but normalization has limited impact on structural changes and mortality.
- Prevention of renal anemia may be a more effective strategy than treatment for improving long-term cardiovascular outcomes.
- Hypertension is a notable side effect of rHuEPO therapy, requiring careful management.
Abstract:
Cardiac diseases account for almost 50% of deaths in long-term dialysis patients. Left ventricular dysfunction is present in approximately 80% of these patients and is highly predictive of future ischemic heart disease, cardiac failure, and death. Anemia has been identified as one of several risk factors responsible for cardiac complications. Cardiovascular consequences of renal anemia begin relatively early in the course of renal failure and progress with the decline of renal function and also during dialysis therapy. In chronic renal failure patients with severe anemia (hemoglobin levels <10 g/dL), increased cardiac output, high left ventricular mass, left ventricular end-diastolic and end-systolic diameters, and cardiac symptoms improve after partial correction of anemia (hemoglobin levels >11 g/dL according to the European Best Practice Guidelines). It is disappointing that normalization of hemoglobin levels has only minor effects with respect to regression of left ventricular hypertrophy and left ventricular dilation. There is no benefit of hemoglobin normalization on all-cause mortality of dialysis patients or on survival of end-stage renal disease patients with congestive heart failure or ischemic heart disease. Therefore, prevention of renal anemia may be more efficient than its treatment. Hypertension is one of the major side effects of recombinant human erythropoietin (rHuEPO) therapy. Multiple factors are involved in rHuEPO-induced hypertension. High blood pressure can usually be controlled readily in the majority of the patients.
Related Concept Videos
01:14Erythropoiesis
01:28Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
01:14Erythropoiesis
01:17Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:24Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...